Key Achievements

CLINUVEL continued its advance towards a diversified biopharmaceutical in the June 2024 financial year

Financial performance

Growth in revenues
Controlled increase in expenses
Eighth consecutive annual profit
Seventh consecutive annual dividend declared
Continued increase in cash reserves

Afamelanotide in the clinic

VP – Phase II study CUV040 completed; European Orphan Drug Designation (ODD) granted
DNA Repair – CUV151 in healthy volunteers completed; CUV152 and CUV156 continue; European ODD granted for XP
Vitiligo – recruitment Phase III study CUV105 commenced
AIS – Phase II study CUV803 underway
Parkinson’s – clinical program CUV901 announced

Steady progress SCENESSE® access in EPP

Increased patients, treatment centres and frequency of dosage
Partnership commenced with Valentech Pharma in Latin America
Adolescent study CUV052 expanded and underway

PhotoCosmetics

Continued formulation work at the Singapore Research, Development & Innovation Centre
Increased awareness of audiences of the need for photoprotection
Prelaunch of CYACÊLLE Radiant

Melanocortin product portfolio

PRÉNUMBRA® in use in clinic for stroke patients
NEURACTHEL® development continued

Reaching more investors and new audiences

Broadening of communications
Novel use of social media
Informative investor briefings
Increased analyst coverage